Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113


Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?

Hanna TP, Nguyen P, Pater J, O'Callaghan CJ, Mittmann N, Earle CC, Tu D, Jonker D, Hay AE.

J Oncol Pract. 2019 Jul 15:JOP1800691. doi: 10.1200/JOP.18.00691. [Epub ahead of print]


Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.

Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ.

Clin Colorectal Cancer. 2019 Mar;18(1):e140-e149. doi: 10.1016/j.clcc.2018.11.006. Epub 2018 Nov 28.


FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group.

N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.


Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.

Cancer Med. 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14.


Comparison of diurnal blood pressure and urine production between people with and without chronic spinal cord injury.

Goh MY, Millard MS, Wong ECK, Berlowitz DJ, Graco M, Schembri RM, Brown DJ, Frauman AG, O'Callaghan CJ.

Spinal Cord. 2018 Sep;56(9):847-855. doi: 10.1038/s41393-018-0081-3. Epub 2018 Mar 2.


Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1.


Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).

Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R; TROG 03.01/CCTG ES.2 group.

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):114-124. doi: 10.1016/S2468-1253(17)30363-1. Epub 2017 Dec 14.


Does left ventricular hypertrophy affect cognition and brain structural integrity in type 2 diabetes? Study design and rationale of the Diabetes and Dementia (D2) study.

Patel SK, Restrepo C, Werden E, Churilov L, Ekinci EI, Srivastava PM, Ramchand J, Wai B, Chambers B, O'Callaghan CJ, Darby D, Hachinski V, Cumming T, Donnan G, Burrell LM, Brodtmann A.

BMC Endocr Disord. 2017 Apr 7;17(1):24. doi: 10.1186/s12902-017-0173-7.


Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators.

N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.


Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, Liu G.

Pharmacogenomics J. 2017 Dec;17(6):535-542. doi: 10.1038/tpj.2016.56. Epub 2016 Nov 29. Review.


Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D.

Pancreatology. 2016 Nov - Dec;16(6):1106-1112. doi: 10.1016/j.pan.2016.08.013. Epub 2016 Aug 30.


Diurnal blood pressure and urine production in acute spinal cord injury compared with controls.

Goh MY, Millard MS, Wong EC, Brown DJ, Frauman AG, O'Callaghan CJ.

Spinal Cord. 2017 Jan;55(1):39-46. doi: 10.1038/sc.2016.100. Epub 2016 Jun 28.


Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.

Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D.

J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.


Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial.

Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich CM, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk S, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura T, Burge ME, Turner J, Tu D, Booth CM.

Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):969-77. doi: 10.1158/1055-9965.EPI-15-1267. Epub 2016 Apr 8.


Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.

Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.


Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.

Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB.

Curr Oncol. 2016 Feb;23(Suppl 1):S7-S13. doi: 10.3747/co.23.2861. Epub 2016 Feb 29.


Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA.

J Thorac Oncol. 2016 Mar;11(3):312-23. doi: 10.1016/j.jtho.2015.11.010. Epub 2015 Dec 31.


Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA.

Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.


Response to 'A retrospective review of sleep disordered breathing, hypertension and cardiovascular diseases in spinal cord injury patients'.

Goh MY, Wong EC, Millard MS, Brown DJ, Berlowitz DJ, O'Callaghan CJ.

Spinal Cord. 2015 Jun;53(6):498. doi: 10.1038/sc.2015.17. Epub 2015 Feb 10. No abstract available.


Cardiopulmonary arrest and mortality trends, and their association with rapid response system expansion.

O'Callaghan CJ.

Med J Aust. 2015 Jan 19;202(1):19-20. No abstract available.


A retrospective review of the ambulatory blood pressure patterns and diurnal urine production in subgroups of spinal cord injured patients.

Goh MY, Wong EC, Millard MS, Brown DJ, O'Callaghan CJ.

Spinal Cord. 2015 Jan;53(1):49-53. doi: 10.1038/sc.2014.192. Epub 2014 Nov 11.


National guidelines for the management of absolute cardiovascular disease risk.

O'Callaghan CJ, Rong P, Goh MY.

Med J Aust. 2014 May 5;200(8):454, 456. No abstract available.


The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17.

Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ.

Acta Oncol. 2014 Jul;53(7):877-84. doi: 10.3109/0284186X.2013.879202. Epub 2014 Feb 5.


Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RP, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S.

Br J Cancer. 2014 Feb 4;110(3):648-55. doi: 10.1038/bjc.2013.753. Epub 2013 Dec 12.


PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.


Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group; Australasian Gastrointestinal Trials Group.

Cancer. 2014 Jan 15;120(2):181-9. doi: 10.1002/cncr.28410. Epub 2013 Oct 11.


Hypertension - the difficult decisions.

O'Callaghan CJ, Goh MY, Rong P.

Aust Fam Physician. 2013 Jun;42(6):376-9. Review.


Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ.

J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20.


Autosomal dominant vasovagal syncope: clinical features and linkage to chromosome 15q26.

Klein KM, Bromhead CJ, Smith KR, O'Callaghan CJ, Corcoran SJ, Heron SE, Iona X, Hodgson BL, McMahon JM, Lawrence KM, Scheffer IE, Dibbens LM, Bahlo M, Berkovic SF.

Neurology. 2013 Apr 16;80(16):1485-93. doi: 10.1212/WNL.0b013e31828cfad0.


Innovative estimation of survival using log-normal survival modelling on ACCENT database.

Chapman JW, O'Callaghan CJ, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG, O'Connell MJ, Sargent DJ.

Br J Cancer. 2013 Mar 5;108(4):784-90. doi: 10.1038/bjc.2013.34. Epub 2013 Feb 5.


Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ.

Ann Oncol. 2013 Apr;24(4):953-60. doi: 10.1093/annonc/mds577. Epub 2012 Nov 8.


Intermittent androgen suppression for rising PSA level after radiotherapy.

Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L.

N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. Erratum in: N Engl J Med. 2012 Dec 6;367(23):2262.


Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.

Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ.

Eur J Cancer. 2012 Jul;48(10):1434-42. doi: 10.1016/j.ejca.2011.10.035. Epub 2011 Nov 24.


Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.

JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.


Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care.

Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O'Callaghan CJ.

Ann Oncol. 2011 Jan;22(1):118-26. doi: 10.1093/annonc/mdq309. Epub 2010 Jul 5.


Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group.

J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.


Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.

Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ.

J Clin Oncol. 2009 Apr 10;27(11):1822-8. doi: 10.1200/JCO.2008.19.6048. Epub 2009 Mar 9.


K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.


Projected effects of climate change on tick phenology and fitness of pathogens transmitted by the North American tick Ixodes scapularis.

Ogden NH, Bigras-Poulin M, Hanincová K, Maarouf A, O'Callaghan CJ, Kurtenbach K.

J Theor Biol. 2008 Oct 7;254(3):621-32. doi: 10.1016/j.jtbi.2008.06.020. Epub 2008 Jun 26.


Risk maps for range expansion of the Lyme disease vector, Ixodes scapularis, in Canada now and with climate change.

Ogden NH, St-Onge L, Barker IK, Brazeau S, Bigras-Poulin M, Charron DF, Francis CM, Heagy A, Lindsay LR, Maarouf A, Michel P, Milord F, O'Callaghan CJ, Trudel L, Thompson RA.

Int J Health Geogr. 2008 May 22;7:24. doi: 10.1186/1476-072X-7-24.


Role of migratory birds in introduction and range expansion of Ixodes scapularis ticks and of Borrelia burgdorferi and Anaplasma phagocytophilum in Canada.

Ogden NH, Lindsay LR, Hanincová K, Barker IK, Bigras-Poulin M, Charron DF, Heagy A, Francis CM, O'Callaghan CJ, Schwartz I, Thompson RA.

Appl Environ Microbiol. 2008 Mar;74(6):1780-90. doi: 10.1128/AEM.01982-07. Epub 2008 Feb 1. Erratum in: Appl Environ Microbiol. 2008 Jun;74(12):3919.


Cetuximab for the treatment of colorectal cancer.

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ.

N Engl J Med. 2007 Nov 15;357(20):2040-8.


End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A; ACCENT Group.

J Clin Oncol. 2007 Oct 10;25(29):4569-74. Epub 2007 Sep 17.


Vector seasonality, host infection dynamics and fitness of pathogens transmitted by the tick Ixodes scapularis.

Ogden NH, Bigras-Poulin M, O'callaghan CJ, Barker IK, Kurtenbach K, Lindsay LR, Charron DF.

Parasitology. 2007 Feb;134(Pt 2):209-27. Epub 2006 Oct 11.


Functional status and health-related quality of life during inpatient stroke rehabilitation.

Madden S, Hopman WM, Bagg S, Verner J, O'Callaghan CJ.

Am J Phys Med Rehabil. 2006 Oct;85(10):831-8; quiz 839-41, 857.


Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.

Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts ME, Drake WM, Monson JP, Trainer PJ, Randeva HS.

J Clin Endocrinol Metab. 2006 Nov;91(11):4635-40. Epub 2006 Aug 22.


Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women.

Lewandowski KC, Komorowski J, Mikhalidis DP, Bienkiewicz M, Tan BK, O'Callaghan CJ, Lewinski A, Prelevic G, Randeva HS.

J Clin Endocrinol Metab. 2006 Aug;91(8):3123-30. Epub 2006 May 16.


Investigation of ground level and remote-sensed data for habitat classification and prediction of survival of Ixodes scapularis in habitats of southeastern Canada.

Ogden NH, Barker IK, Beauchamp G, Brazeau S, Charron DF, Maarouf A, Morshed MG, O'Callaghan CJ, Thompson RA, Waltner-Toews D, Waltner-Toews M, Lindsay LR.

J Med Entomol. 2006 Mar;43(2):403-14.


Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome.

Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, Randeva HS.

J Clin Endocrinol Metab. 2006 Mar;91(3):1173-7. Epub 2005 Dec 6.


Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A.

J Clin Oncol. 2005 Dec 1;23(34):8664-70. Epub 2005 Oct 31.


Supplemental Content

Loading ...
Support Center